Literature DB >> 26591553

[Impact of chronic obstructive pulmonary disease on one-year prognosis in patients with ST-segment elevation myocardial infarction].

O M Polikutina1, Yu S Slepynina1, E D Bazdyrev1, V N Karetnikova1, O L Barbarach1.   

Abstract

AIM: To assess the role of chronic obstructive pulmonary disease (COPD) in the development of unfavorable outcomes of long-term (one-year) prognosis of ST-elevation myocardial infarction (STEMI). SUBJECTS AND METHODS: A total of 529 patients diagnosed with STEMI and no age limits were examined. Group 1 included 65 (12.3%) patients with previously diagnosed COPD; Group 2 consisted of 464 (87.7%) patients without COPD. One-year prognosis was studied in 384 (81.5%) patients. The investigators evaluated the following endpoints: evolving recurrent myocardial infarction (MI), progressive angina pectoris, decompensated chronic heart failure (CHF), repeat percutaneous coronary interventions, stroke, and death.
RESULTS: The prevalence of COPD was 12.3% in the patients with STEM]. Unfavorable one-year prognosis was significantly more often registered in the comorbidity group regardless of age, gender, and smoking status. COPD increased the risk of combined endpoints by 1.9 times within a year after MI and that of decompensated CHD by 2.6 times during a year after STEM.
CONCLUSION: COPD may be an independent risk factor for unfavorable outcomes during a year after MI.

Entities:  

Mesh:

Year:  2015        PMID: 26591553     DOI: 10.17116/terarkh201587952-57

Source DB:  PubMed          Journal:  Ter Arkh        ISSN: 0040-3660            Impact factor:   0.467


  1 in total

1.  Comparison of SYNTAX score II efficacy with SYNTAX score and TIMI risk score for predicting in-hospital and long-term mortality in patients with ST segment elevation myocardial infarction.

Authors:  Yavuz Karabağ; Metin Çağdaş; Ibrahim Rencuzogullari; Süleyman Karakoyun; İnanç Artaç; Doğan İliş; Mahmut Yesin; Mesut Öterkus; Tayyar Gokdeniz; Cengiz Burak; Ibrahim Halil Tanboğa
Journal:  Int J Cardiovasc Imaging       Date:  2018-03-14       Impact factor: 2.357

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.